Indication
Kidney Transplant Rejection
19 clinical trials
24 products
Product
TX200-TR101Clinical trial
Multicentre Open-Label Single Ascending Dose Dose-Ranging Phase I/IIa Study to Evaluate Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor TRegulatory Cell Therapy in Living Donor Renal Transplant RecipientsStatus: Active (not recruiting), Estimated PCD: 2024-11-13
Clinical trial
AT-1501-K207: BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney TransplantationStatus: Recruiting, Estimated PCD: 2025-03-01
Product
AT-1501Product
TacrolimusProduct
ImlifidaseClinical trial
A Prospective, Observational Long-term Follow-up Trial of Kidney Transplant Patients Treated With Imlifidase or Plasma Exchange After an Active/Chronic Active Antibody-Mediated Rejection EpisodeStatus: Terminated, Estimated PCD: 2023-03-30
Clinical trial
AT-1501-K209: BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant RecipientsStatus: , Estimated PCD: 2029-12-01
Clinical trial
A Phase 2 Prospective, Multi-center, Open-label Trial to Assess the Safety & Efficacy of Cellular Immunotherapy With MDR-103 for Induction of Mixed Chimerism & Immune Tolerance in Past Recipients of HLA Zero-mismatch, LD Kidney TransplantsStatus: Not yet recruiting, Estimated PCD: 2025-08-01
Product
MDR-103Product
MDR-101Clinical trial
A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney TransplantsStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
MDR-102Product
Immunosuppressive AgentsClinical trial
A Phase 2/3, Prospective, Randomized, Multi-center, Open-Label, Controlled Trial to Assess the Efficacy & Safety of Cellular Immunotherapy With MDR-102 for Induction of Immune Quiescence™in Recipients of HLA-mismatched, LD Kidney TransplantsStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
SIMPLE Study: A Prospective and Randomized Trial of a Simplified Immunosuppressive Protocol Utilizing Low Dose EnvarsusXRStatus: Recruiting, Estimated PCD: 2025-02-01
Product
BasiliximabProduct
MethylprednisoloneProduct
AzathioprineClinical trial
Desensitization in Kidney Allograft Recipients Before Transplantation Using DaratumumabStatus: Completed, Estimated PCD: 2023-06-01
Product
DaratumumabClinical trial
Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)Status: Not yet recruiting, Estimated PCD: 2031-03-01
Product
BelatacepClinical trial
Immune Monitoring to Facilitate Belatacept MonotherapyStatus: Completed, Estimated PCD: 2021-09-30
Product
Immunosuppression reductionProduct
Envarsus XRClinical trial
Induction Therapy of Thymoglobulin Versus Basiliximab in the Prevention of Acute Rejection After Pediatric Kidney TransplantationStatus: Completed, Estimated PCD: 2022-07-27
Product
Rabbit ATGClinical trial
Efficacy of Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5 Guided Dosing Versus Weight-based Dosing in a Multi-ethnic Population of Kidney Transplant Recipients in SingaporeStatus: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
A Prospective, Pilot Trial to Compare the Efficacy of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release on Suppression of Donor-Specific Antibodies in HLA Sensitized Kidney Transplant RecipientsStatus: Active (not recruiting), Estimated PCD: 2023-07-21
Product
Extended-release tacrolimusProduct
Immediate-release tacrolimusClinical trial
The Efficacy of Donor-derived Cell-free DNA as a Biomarker for Subclinical Antibody-mediated Rejection in de Novo Anti-HLA DSA-positive Recipients Who Maintain Stable Renal Function After Kidney TransplantationStatus: Recruiting, Estimated PCD: 2024-11-30
Product
AlloSeqClinical trial
Cf-DNA Assay During Treatment of Acute Rejection-Pilot StudyStatus: Completed, Estimated PCD: 2023-09-05
Product
cf-DNAClinical trial
A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) As an Agent to Eliminate Donor Specific HLA Antibodies and Improve Outcomes of Patients With Chronic & Active Antibody-Mediated Rejection Post-Kidney TransplantationStatus: Completed, Estimated PCD: 2024-04-16
Product
ClazakizumabClinical trial
Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients：A Large, Multiple-Center Prospective StudyStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
Autologous Mesenchymal Stromal Cells to Induce Tolerance in Living-donor Kidney Transplant RecipientsStatus: Terminated, Estimated PCD: 2023-05-29
Product
Mesenchymal Stromal Cells